Non-insulin Antidiabetic Agents The choice of glucose-lowering therapy is a critical determinant of hypoglycemia risk
Although rare, its also crucial to be aware of potential risks: Kidney health: Stay hydrated with 1.5-2L fluids to prevent dehydration and kidney issues
As we noted in a recent update and earlier this year, telehealth companies, compounding pharmacies, medspas and other businesses promoting, manufacturing or facilitating access to compounded GLP-1 drugs should audit their advertising practices to take into account recent challenges and FDA activity
Nausea, abdominal discomfort, or gastroesophageal refluxall documented with tirzepatidecan interfere with sleep onset and maintenance
Tin Wui Wong Jie Liu, 1 3, * Peng Ge, 1 3, * Yalan Luo, 4, * Zhenxuan Sun, 1 3 Xinyu Luo, 1 3 Huijuan Li, 5 Boliang Pei, 1 3 Lu Xun, 1 3 Xuetao Zhang, 1 3 Yunfei Jiang, 1 3 Haiyun Wen, 1 3 Jin Liu, 1 3 Qi Yang, 6 Shurong Ma, 1 3 Hailong Chen 1 3 1 Department of General Surgery, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, 116011, Peoples Republic of China
A small percentage of users experience ongoing constipation or acid reflux throughout treatment